Adjusting for confounding effects of treatment switching in a randomized phase II study of dabrafenib plus trametinib in BRAF V600+ metastatic melanoma.
about
Adjusting for confounding effects of treatment switching in a randomized phase II study of dabrafenib plus trametinib in BRAF V600+ metastatic melanoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Adjusting for confounding effe ...... RAF V600+ metastatic melanoma.
@en
type
label
Adjusting for confounding effe ...... RAF V600+ metastatic melanoma.
@en
prefLabel
Adjusting for confounding effe ...... RAF V600+ metastatic melanoma.
@en
P1433
P1476
Adjusting for confounding effe ...... RAF V600+ metastatic melanoma.
@en
P2093
Mayur M Amonkar
P304
P356
10.1097/CMR.0000000000000193
P407
P577
2015-09-03T00:00:00Z